Quince Therapeutics, Inc.
QNCX
$1.61
$0.010.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -100.49% | -81.07% | -90.06% | -73.63% | 28.37% |
| Total Depreciation and Amortization | -48.41% | -42.24% | 690.00% | 288.00% | 88.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 242.94% | 133.67% | 145.97% | 147.97% | -51.18% |
| Change in Net Operating Assets | 647.81% | -124.48% | -5,222.50% | -749.59% | 90.07% |
| Cash from Operations | -43.66% | -74.42% | -68.60% | -40.45% | 26.78% |
| Capital Expenditure | -480.95% | -60.63% | 30.84% | 61.36% | 76.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -119.98% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11,933.17% | 720.52% | 144.63% | 415.97% | 43.06% |
| Cash from Investing | 1,102.18% | 480.48% | 118.56% | 362.21% | -123.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Common Stock | -56.89% | 51.01% | 206.52% | 204.17% | 48.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,823.67% | -3,439.16% | -7,038.24% | 450.94% | 109.63% |
| Foreign Exchange rate Adjustments | -65.22% | 188.75% | -183.92% | -104.63% | -31.34% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.61% | 38.98% | -86.27% | 39.20% | -19.43% |